A citation-based method for searching scientific literature

Michele Correale, Olga Lamacchia, Michele Ciccarelli, Giuseppe Dattilo, Lucia Tricarico, Natale Daniele Brunetti. Heart Fail Rev 2021
Times Cited: 4







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
75

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Liang Xu, Naoto Nagata, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Guanliang Chen, Eric Mayoux, Shuichi Kaneko, Tsuguhito Ota. EBioMedicine 2017
161
50

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Sherif F Nagueh, Otto A Smiseth, Christopher P Appleton, Benjamin F Byrd, Hisham Dokainish, Thor Edvardsen, Frank A Flachskampf, Thierry C Gillebert, Allan L Klein, Patrizio Lancellotti,[...]. J Am Soc Echocardiogr 2016
25

Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction.
Mads Ersbøll, Nana Valeur, Ulrik Madvig Mogensen, Mads Jønsson Andersen, Jacob Eifer Møller, Eric J Velazquez, Christian Hassager, Peter Søgaard, Lars Køber. J Am Coll Cardiol 2013
240
25

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
25

Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
Michele Correale, Renata Petroni, Stefano Coiro, Elena-Laura Antohi, Francesco Monitillo, Marta Leone, Marco Triggiani, Shiro Ishihara, Hans-Dirk Dungen, Chaudhry M S Sarwar,[...]. Heart Fail Rev 2021
2
50

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Roberto M Lang, Luigi P Badano, Victor Mor-Avi, Jonathan Afilalo, Anderson Armstrong, Laura Ernande, Frank A Flachskampf, Elyse Foster, Steven A Goldstein, Tatiana Kuznetsova,[...]. Eur Heart J Cardiovasc Imaging 2015
25

Prognostic significance of left ventricular mass change during treatment of hypertension.
Richard B Devereux, Kristian Wachtell, Eva Gerdts, Kurt Boman, Markku S Nieminen, Vasilios Papademetriou, Jens Rokkedal, Katherine Harris, Peter Aurup, Björn Dahlöf. JAMA 2004
601
25

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
Mikkel Jürgens, Morten Schou, Philip Hasbak, Andreas Kjær, Emil Wolsk, Bo Zerahn, Mikkel Wiberg, Niels Høgh Brandt, Peter Haulund Gæde, Peter Rossing,[...]. BMJ Open 2019
3
33

Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
Tamique Mason, Otavio R Coelho-Filho, Subodh Verma, Biswajit Chowdhury, Fei Zuo, Adrian Quan, Kevin E Thorpe, Christopher Bonneau, Hwee Teoh, Richard E Gilbert,[...]. JACC Cardiovasc Imaging 2021
16
25


Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Massar Omar, Jesper Jensen, Mulham Ali, Peter H Frederiksen, Caroline Kistorp, Lars Videbæk, Mikael Kjær Poulsen, Christian D Tuxen, Sören Möller, Finn Gustafsson,[...]. JAMA Cardiol 2021
24
25

Myocardial composition and function in diabetes. The effects of chronic insulin use.
T J Regan, C F Wu, C K Yeh, H A Oldewurtel, B Haider. Circ Res 1981
142
25

Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries.
Katherine H Chau, Pamela S Douglas, Philippe Pibarot, Rebecca T Hahn, Omar K Khalique, Wael A Jaber, Paul Cremer, Neil J Weissman, Federico M Asch, Yiran Zhang,[...]. J Am Coll Cardiol 2020
29
25

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
266
25

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Kim A Connelly, Yanling Zhang, Jean-François Desjardins, Linda Nghiem, Aylin Visram, Sri N Batchu, Verra G Yerra, Golam Kabir, Kerri Thai, Andrew Advani,[...]. Cardiovasc Diabetol 2020
20
25

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
25

Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial.
Mie K Eickhoff, Flemming J Olsen, Marie Frimodt-Møller, Lars J Diaz, Jens Faber, Magnus T Jensen, Peter Rossing, Frederik Persson. J Diabetes Complications 2020
5
25

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
986
25

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial.
Subodh Verma, C David Mazer, Deepak L Bhatt, Satish R Raj, Andrew T Yan, Atul Verma, Ele Ferrannini, Gudrun Simons, Jisoo Lee, Bernard Zinman,[...]. Diabetes Care 2019
14
25

Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Salva R Yurista, Herman H W Silljé, Silke U Oberdorf-Maass, Elisabeth-Maria Schouten, Mario G Pavez Giani, Jan-Luuk Hillebrands, Harry van Goor, Dirk J van Veldhuisen, Rudolf A de Boer, B Daan Westenbrink. Eur J Heart Fail 2019
122
25

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
25

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, Kenneth Mangion, Giles Roditi, Ross T Campbell, Colin Berry, Victor Chong, Liz Coyle, Kieran F Docherty,[...]. Circulation 2021
82
25

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
25

Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
Matthew Griffin, Veena S Rao, Juan Ivey-Miranda, James Fleming, Devin Mahoney, Christopher Maulion, Nisha Suda, Krishmita Siwakoti, Tariq Ahmad, Daniel Jacoby,[...]. Circulation 2020
104
25


Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.
Kåre I Birkeland, Johan Bodegard, Jan W Eriksson, Anna Norhammar, Hermann Haller, Gerard C M Linssen, Amitava Banerjee, Marcus Thuresson, Suguru Okami, Elena Garal-Pantaler,[...]. Diabetes Obes Metab 2020
34
25

Measuring Water Distribution in the Heart: Preventing Edema Reduces Ischemia-Reperfusion Injury.
Mireia Andrés-Villarreal, Ignasi Barba, Marcos Poncelas, Javier Inserte, José Rodriguez-Palomares, Victor Pineda, David Garcia-Dorado. J Am Heart Assoc 2016
10
25

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.
Mikkel Jürgens, Morten Schou, Philip Hasbak, Andreas Kjær, Emil Wolsk, Bo Zerahn, Mikkel Wiberg, Niels H Brandt-Jacobsen, Peter Gæde, Peter Rossing,[...]. J Am Heart Assoc 2021
4
25

Diastolic properties, myocardial water content, and histologic condition of the rat left ventricle: effect of varied osmolarity of a coronary perfusate.
Y M Carter, C X Jia, P F Soto, J P Starr, D G Rabkin, D T Hsu, P E Fisher, H M Spotnitz. J Heart Lung Transplant 1998
11
25

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Carlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez,[...]. J Am Coll Cardiol 2021
95
25

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
200
25

The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus.
A Dawson, A D Morris, A D Struthers. Diabetologia 2005
63
25

Evidence for cardiomyopathy in familial diabetes mellitus.
T J Regan, M M Lyons, S S Ahmed, G E Levinson, H A Oldewurtel, M R Ahmad, B Haider. J Clin Invest 1977
626
25

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
355
25

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
John J V McMurray, Hertzel C Gerstein, Rury R Holman, Marc A Pfeffer. Lancet Diabetes Endocrinol 2014
205
25

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
25

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Michael R MacDonald, Mark C Petrie, Fumi Varyani, Jan Ostergren, Eric L Michelson, James B Young, Scott D Solomon, Christopher B Granger, Karl Swedberg, Salim Yusuf,[...]. Eur Heart J 2008
386
25


Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
Andrea Passantino, Caterina Rizzo, Domenico Scrutinio, Alberto Palazzuoli. Heart Fail Rev 2021
1
100

Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond.
Angela Sciacqua, Elena Succurro, Giuseppe Armentaro, Sofia Miceli, Daniele Pastori, Giuseppe Rengo, Giorgio Sesti. Heart Fail Rev 2021
4
25

Prognostic impact of diabetes in chronic and acute heart failure.
Stefano Ghio, Valentina Mercurio, Andrea Attanasio, Gaetano Asile, Carlo Gabriele Tocchetti, Stefania Paolillo. Heart Fail Rev 2021
1
100

Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.
Francesca Romana Prandi, Isabella Evangelista, Domenico Sergi, Alberto Palazzuoli, Francesco Romeo. Heart Fail Rev 2022
2
50

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient.
Paolo Severino, Andrea D'Amato, Silvia Prosperi, Bettina Costi, Danilo Angotti, Lucia Ilaria Birtolo, Cristina Chimenti, Carlo Lavalle, Viviana Maestrini, Massimo Mancone,[...]. Heart Fail Rev 2021
3
33

Impact of diabetes on cardiopulmonary function: the added value of a combined cardiopulmonary and echocardiography stress test.
Nicola Riccardo Pugliese, Alessandra Pieroni, Nicolò De Biase, Valerio Di Fiore, Lorenzo Nesti, Piergiuseppe Agostoni, Frank Lloyd Dini. Heart Fail Rev 2021
3
33

Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction.
Daniele Masarone, Roberta Pacileo, Giuseppe Pacileo. Heart Fail Rev 2021
2
50

Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure.
Alessandra Dei Cas, Sadiya S Khan, Javed Butler, Robert J Mentz, Robert O Bonow, Angelo Avogaro, Diethelm Tschoepe, Wolfram Doehner, Stephen J Greene, Michele Senni,[...]. JACC Heart Fail 2015
180
25


Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
Ovidiu Chioncel, Mitja Lainscak, Petar M Seferovic, Stefan D Anker, Maria G Crespo-Leiro, Veli-Pekka Harjola, John Parissis, Cecile Laroche, Massimo Francesco Piepoli, Candida Fonseca,[...]. Eur J Heart Fail 2017
292
25

Epigenetic changes in bone marrow progenitor cells influence the inflammatory phenotype and alter wound healing in type 2 diabetes.
Katherine A Gallagher, Amrita Joshi, William F Carson, Matthew Schaller, Ronald Allen, Sumanta Mukerjee, Nico Kittan, Eva L Feldman, Peter K Henke, Cory Hogaboam,[...]. Diabetes 2015
108
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.